Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Statistical biases due to anonymization evaluated in an open clinical dataset from COVID-19 patients.
Koll CEM, Hopff SM, Meurers T, Lee CH, Kohls M, Stellbrink C, Thibeault C, Reinke L, Steinbrecher S, Schreiber S, Mitrov L, Frank S, Miljukov O, Erber J, Hellmuth JC, Reese JP, Steinbeis F, Bahmer T, Hagen M, Meybohm P, Hansch S, Vadász I, Krist L, Jiru-Hillmann S, Prasser F, Vehreschild JJ; NAPKON Study Group. Koll CEM, et al. Among authors: frank s. Sci Data. 2022 Dec 21;9(1):776. doi: 10.1038/s41597-022-01669-9. Sci Data. 2022. PMID: 36543828 Free PMC article.
Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate-to-severe ARDS-a randomized, placebo-controlled, double-blind trial.
Schmid B, Kredel M, Ullrich R, Krenn K, Lucas R, Markstaller K, Fischer B, Kranke P, Meybohm P, Zwißler B, Frank S; and the Solnatide Collaborators Group. Schmid B, et al. Among authors: frank s. Trials. 2021 Sep 20;22(1):643. doi: 10.1186/s13063-021-05588-9. Trials. 2021. PMID: 34544463 Free PMC article. Clinical Trial.
Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate to severe ARDS in a randomized, placebo-controlled, double-blind trial: preliminary evaluation of safety and feasibility in light of the COVID-19 pandemic.
Schmid B, Kranke P, Lucas R, Meybohm P, Zwissler B, Frank S. Schmid B, et al. Among authors: frank s. Trials. 2022 Apr 4;23(1):252. doi: 10.1186/s13063-022-06182-3. Trials. 2022. PMID: 35379296 Free PMC article. Clinical Trial.
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y, Strobl R, Apfelbacher C, Bahmer T, Geisler R, Heuschmann P, Horn A, Hoven H, Keil T, Krawczak M, Krist L, Lemhöfer C, Lieb W, Lorenz-Depiereux B, Mikolajczyk R, Montellano FA, Reese JP, Schreiber S, Skoetz N, Störk S, Vehreschild JJ, Witzenrath M, Grill E; NAPKON Study Group. Shi Y, et al. Infection. 2023 Dec;51(6):1679-1694. doi: 10.1007/s15010-023-02043-6. Epub 2023 May 25. Infection. 2023. PMID: 37231313 Free PMC article.
Effect of acyclovir therapy on the outcome of mechanically ventilated patients with lower respiratory tract infection and detection of herpes simplex virus in bronchoalveolar lavage: protocol for a multicentre, randomised controlled trial (HerpMV).
Hagel S, Brillinger N, Decker S, Deja M, Ertmer C, Fiedler S, Franken P, Heim M, Weigand MA, Zarbock A, Pletz MW; SepNet Critical Care Trials Group. Hagel S, et al. BMJ Open. 2024 Apr 25;14(4):e082512. doi: 10.1136/bmjopen-2023-082512. BMJ Open. 2024. PMID: 38670599 Free PMC article. Clinical Trial.
Effects of the "ICU Support" team meeting concept on patient-centered and staff-centered outcomes: study protocol for a randomized controlled multicenter study.
Thommes MS, Klasen M, Bickenbach J, Deja M, Engelhard K, Francis R, Gramatté J, Hempel G, Gmeinwieser K, Reedy G, Röder D, Schroeder I; HUMAN-NET CONSORTIUM; Sopka S. Thommes MS, et al. Trials. 2023 Nov 26;24(1):756. doi: 10.1186/s13063-023-07754-7. Trials. 2023. PMID: 38008760 Free PMC article.
2,330 results